Drug Trial Radar · NCT04993352
Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD
Last checked: Nov 20, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jul 15, 2021
Primary completion
Jul 7, 2022
Study completion Mar 13, 2023
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HLX04-O administered every 4 weeks in participants with wet age-related macular degeneration (wAMD)
Conditions
- Age Related Macular Degeneration
Interventions
recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injectionDrug
0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Safety eventsTime frame: week 4
- Phase 2: Mean change of letters from baseline in the BCVA at Week 12Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
XuZhou Central Hospital
Xuzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.